TMEM132A promotes cervical cancer progression via HOMER3-mediated activation of FAK/PI3K/AKT signaling pathway Authors: Fengyi Sun, Zhe Wang Published: 2026 ABSTRACT TMEM132A is aberrantly expressed in multiple solid tumors, yet its role and mechanism in cervical cancer (CC) remain unclear. TMEM132A expression was analyzed using TCGA and GEO datasets and validated in CC cell lines and paired clinical tissues via qRT-PCR and Western blotting. Functional assays were systematically performed to evaluate the oncogenic roles of TMEM132A. Downstream pathways were explored through GSEA and co-expression analysis, with mechanistic interactions confirmed via TMEM132A/HOMER3 gain- and loss-of-function rescue experiments. TMEM132A was significantly upregulated in CC tissues and cell lines, correlating with aggressive tumor phenotypes. TMEM132A overexpression enhanced cell proliferation, migration, invasion, and S-phase progression, whereas its knockdown exerted opposite effects. Mechanistically, TMEM132A activated the FAK/PI3K/AKT pathway by positively regulating HOMER3. Silencing HOMER3 effectively abrogated TMEM132A-induced pathway activation and malignant behaviors. This study is the first to demonstrate that TMEM132A promotes CC progression through HOMER3-dependent stimulation of the FAK/PI3K/AKT axis. These findings position TMEM132A as a candidate molecular marker for future clinical evaluation and a potential node for subsequent therapeutic exploration in CC. Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-54987-y. Introduction Cervical cancer (CC) is the 4th most predominant cancer in women globally, accounts for approximately 340,000 deaths yearly, with persistent infection by high-risk human papillomavirus (HPV) considered as the key etiological factor1. Although the prevalent application of HPV vaccination and advances in screening technologies have significantly decreased the occurrence of early-stage disease, treating the advanced or recurrent metastatic CC is still a major clinical challenge, distinguished by a 5-year survival rate < 20%2. Current treatment modalities, including surgery, chemoradiotherapy, and targeted therapies, demonstrate limited efficacy in controlling metastatic disease and are frequently hampered by developing the drug resistance3. Hence, a deeper comprehension of the molecular mechanisms of CC progression and the demonstration of new therapeutic targets are urgently warranted. The TMEM family consists of phylogenetically related integral membrane proteins whose physiological functions are not yet fully understood. These proteins are currently designated by numerical identifiers under the “transmembrane protein” (TMEM) classification system4. Structurally, they typically contain transmembrane domains composed of either α-helices or β-sheets, which traverse the phospholipid bilayer and give rise to distinct intra- and extracellular regions as well as membrane-embedded segments5. They are localized to a variety of subcellular compartments, such as the plasma membrane, the trans-Golgi network, the endoplasmic reticulum, lysosomal membranes, mitochondria, and the nuclear envelope. These localizations have been determined through experimental studies or bioinformatic predictions. As functional insights emerge, some TMEM proteins are reclassified into more specific families6. For instance, TMEM16A is considered anoctamin 1, a calcium-stimulated chloride channel, and TMEM206 is now recognized as PAC, a proton-activated chloride channel7,8. These examples illustrate the potential of the TMEM family to serve as a rich source of previously uncharacterized membrane-associated functions. Continued research into TMEM proteins is expected to reveal novel regulatory mechanisms and may result in the determination of innovative therapeutic targets in the field of membrane biology. TMEM132A, a part of the TMEM132 protein family, includes five structurally related proteins designated as TMEM132A through TMEM132E. All of these family members share a conserved molecular architecture composed of three tandem immunoglobulin-like domains and a coiled-coil domain homolog9. Emerging evidence underscores the significance of TMEM132A in cancer development. Wang and colleagues illustrated that overexpression of TMEM132A is linked to poor prognosis in individuals with prostate cancer, and that silencing its expression markedly suppresses the growth of prostate malignant cells10. In addition, a pan-cancer analysis conducted by Zhang et al., which integrated data from multiple genomic databases, revealed widespread overexpression of TMEM132A across various malignancies. This overexpression was linked to adverse clinical outcomes, including reduced survival and more aggressive disease phenotypes11. While these outcomes present initial insights into the oncogenic functions and molecular mechanisms of TMEM132A in multiple cancer types, its expression pattern, biological roles, and interactions with the tumor microenvironment in CC remain to be fully characterized. HOMER3, a part of the HOMER protein family, acts as an evolutionarily conserved scaffold protein. It contains an N-terminal Ena/VASP Homology 1 (EVH1) domain, which specifically interacts with signaling molecules harboring the PPXXF motif (e.g., metabotropic glutamate and IP3 receptors and Trp channels). Through these interactions, HOMER3 has a vital function in regulating intracellular calcium homeostasis, cytoskeletal reorganization, and G protein-coupled receptor (GPCR) signal transduction12. Accumulating studies indicate that HOMER3 exerts tissue-specific functions in cancer progression. For example, in non-small cell lung cancer, HOMER3 promotes tumor growth and metastasis via GABPB1-mediated regulation of mitochondrial metabolism13. In hepatocellular carcinoma, it facilitates disease progression by overexpressing EZH2 and modulating the miR-361/GPNMB signaling axis14. Furthermore, HOMER3 has been shown to regulate neuronal plasticity through the formation of postsynaptic signaling complexes, underscoring its functional versatility15. Despite these findings, the expression pattern, biological functions, and potential involvement in classical oncogenic pathways, such as the FAK/PI3K/AKT axis, have not been well defined in CC. Moreover, its possible regulatory role in TMEM132A-induced tumor progression remains to be clarified. Addressing this knowledge gap may uncover novel molecular mechanisms and provide insights into potential targeted therapeutic approaches for CC. Although the roles of TMEM132A and HOMER3 have begun to emerge in other types of malignancies, their biological significance in CC remains largely undefined. The oncogenic potential of TMEM132A in CC has not yet been established, and it is still unknown whether its function relies on the regulation of specific downstream effectors. Moreover, the exact contribution of HOMER3 to CC progression, as well as its potential involvement in well-characterized oncogenic pathways such as FAK/PI3K/AKT, has been unclarified. This investigation aims to comprehensively examine the function of TMEM132A in CC progression and to elucidate the underlying molecular mechanism through its interaction with HOMER3, thereby providing mechanistic insights that may inform the creation of innovative therapeutic approaches targeting the TMEM132A–HOMER3 signaling axis. Materials and methods Database The TCGA-CESC (Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma) RNA-seq dataset was brought from TCGA (https://portal.gdc.cancer.gov), comprising 304 tumor tissues and 13 neighboring healthy tissues. The GSE9750 dataset (GPL96, [HG-U133A] Affymetrix Human Genome U133A Array) was downloaded from the GEO (https://www.ncbi.nlm.nih.gov/geo/), including 33 primary CC tissues and 24 healthy cervical epithelial samples. Both datasets were utilized for analyzing TMEM132A expression profiles and validating differential expression patterns. Bioinformatics The limma R was utilized for differential expression analysis, with normalized expression values (FPKM for TCGA and RMA-processed for GEO) to identify genes showing significant dysregulation (|log2FC| > 1, FDR < 0.05). The diagnostic potential of TMEM132A was estimated via receiver operating characteristic (ROC) curve analysis via the pROC package, with bootstrap resampling (1,000 iterations) to calculate confidence intervals. Co-expression networks were constructed by calculating Pearson correlation coefficients (|r| > 0.3, p < 0.01) and visualized via the pheatmap package. Functional enrichment analyses (KEGG and GO) were conducted via the DAVID platform, while GSEA was implemented via GSEA software (v4.1.0) to identify pathway-level alterations. KEGG pathway analysis based on data from Kanehisa Laboratories (https://www.kegg.jp/)16. Statistical significance was set as FDR < 0.25 for GSEA and p.adj < 0.05 for other analyses. All visualizations, including volcano plots and survival curves, were generated via ggplot2 and survminer packages in R. Clinical samples Clinical specimens, including 6 paired CC tissues and neighboring healthy tissues, were acquired from individuals undergoing surgical resection at Weifang People’s Hospital. The collection of samples began in February 2024 and concluded in June 2024. Informed consent was waived for this study as approved by the ethics committee. All tissues were promptly snap-frozen in liquid nitrogen and stored at − 80 °C until RNA and protein extraction. This investigation was approved by the Institutional Ethics Committee of Weifang People’s Hospital (Approval No. KYLL20250117-3) and conducted in accordance with the Declaration of Helsinki. Cell culture An incubation of the human CC cell lines (C-33 A, SiHa, and CaSki) and the typical cervical epithelial cell line HcerEpic was conducted in humidified conditions (37 °C, 5% CO₂). CaSki cells were kept in RPMI-1640 medium enriched with 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin. C-33 A, SiHa, and HcerEpic cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) (all from Gibco) with 10% FBS and 1% penicillin–streptomycin. For transfection, cells were plated into plates with six wells and transfection was conducted at 60%–70% confluency via Lipofectamine 3000 (Invitrogen) as per the manufacturer’s guidelines. Transfection of TMEM132A overexpression plasmids (oe TMEM132A) and short hairpin RNA (sh TMEM132A) constructs (or scrambled shRNA as negative control, sh NC) was conducted into SiHa cells. Transfection efficiency was validated 48 h post-transfection via Western blot and qRT-PCR. Western blot assay Total protein isolation from tissues and cultured cells was conducted via RIPA lysis buffer (Beyotime) enriched with protease and phosphatase suppressors. Protein levels were detected via the Bicinchoninic Acid (BCA) assay (Beyotime). A 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gel (Solarbio) was utilized to separate equal protein amounts (20–30 µg), followed by transferring to PVDF membranes (Bio-Rad). A 1-h blockage of membranes was conducted with 5% non-fat milk in TBST at room temperature and an overnight incubation was conducted at 4 °C with primary antibodies against TMEM132A (1:2000, 25301-1-AP, Proteintech), HOMER3 (ab97438), p-FAK (ab81298), FAK (ab40794), p-PI3K (ab182651), PI3K (ab302958), p-AKT (ab38449), AKT (ab8933), and GAPDH (ab8245) (All from Abcam, all 1:1000 except GAPDH 1:5000). After three TBST washes, an incubation of membranes was conducted with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000, ab6721, Abcam) for 1 h at room temperature. The detection of protein signals was conducted via an enhanced chemiluminescence (ECL) system (Bio-Rad), and quantification of band intensities was conducted in ImageJ (NIH) using GAPDH as the loading control. Co-immunoprecipitation (Co-IP) assay SiHa cells were lysed in ice-cold IP lysis buffer (Beyotime) supplemented with protease and phosphatase inhibitors. After centrifugation at 12,000 rpm for 15 min at 4 °C, supernatants were pre-cleared with Protein A/G agarose beads (Thermo Fisher Scientific) for 1 h. Cleared lysates (500 µg protein) were incubated overnight at 4 °C with anti-TMEM132A antibody or normal IgG control. Immune complexes were captured with Protein A/G beads for 2 h, washed five times with lysis buffer, and eluted in 2× SDS loading buffer. Eluates were analyzed by Western blot using anti-HOMER3 and anti-TMEM132A antibodies. QRT-PCR Total RNA isolation from tissues and cultivated cells was conducted via TRIzol reagent (Invitrogen) as per the manufacturer’s guidelines. A NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific) was employed to estimate the RNA level and purity. PrimeScript RT Master Mix (Takara) was utilized to synthesize 1st-strand cDNA synthesis from total RNA (1 µg) at 37 °C for 15 min and 85 °C for 5 s. qRT-PCR was conducted on a QuantStudio 5 Real-Time PCR System (Applied Biosystems) via SYBR Green Premix Ex Taq II (Takara) in a 20 µL reaction. The thermocycling program consisted of 95 °C for 30 s, then 40 cycles of 95 °C for 5 s and 60 °C for 30 s. These are the primer sequences: TMEM132A: F 5′- AGGAGGAGGAGGAAGAGGAGGAG-3′, R 5′- GGACGAAGACCACACCATTGACC-3′ HOMER3: F 5′- GACCCAGCCACCAAGCGAAAC-3′, R 5′- CGCCTCCGATGCTGATGATGC-3′ GAPDH: F 5′- GTGGACCTGACCTGCCGTCTAG-3′, R 5′- GAGTGGGTGTCGCTGTTGAAGTC-3′ Relative gene levels were measured via the 2−ΔΔCt technique, normalized to GAPDH. Melting curve analysis confirmed amplification specificity. Cell proliferation assessment The CCK-8 assay (Dojindo) was employed to estimate cell proliferation as per the manufacturer’s guidelines. SiHa cells transfected with oeTMEM132A, shTMEM132A, or respective controls (vector and shNC) were plated in plates with 96 wells (3 × 10³ cells/well) in 100 µL complete medium. A 10 µL CCK-8 reagent was applied per well at 0, 24, 48, 72, and 96 h, and incubation was conducted at 37 °C for 2 h. A microplate reader (BioTek Synergy H1) was utilized to read absorbance at 450 nm, and cell viability was estimated compared to the 0 h control. Cell apoptosis assay Apoptosis was estimated via the Annexin V-FITC/PI Apoptosis Detection Kit (BD Biosciences) as per the manufacturer’s guidelines. Forty-eight hours post-transfection, SiHa cells transfected with oeTMEM132A, shTMEM132A, or controls (vector and shNC) were collected, rinsed twice with cold PBS, followed by resuspension in 1× binding buffer, and 5 µL Annexin V-FITC and 5 µL propidium iodide (PI) were utilized for staining (15 min, room temperature, darkness). Flow cytometry (BD FACSCanto II, BD Biosciences) was utilized to immediately assess the cells, and data processing was conducted via FlowJo v10.8.1 to detect the viable (Annexin V−/PI−), late apoptotic/necrotic (Annexin V+/PI+), early apoptotic (Annexin V+/PI−), and dead (Annexin V−/PI+) cell proportions. Cell cycle analysis Cell cycle distribution was estimated via PI staining combined with flow cytometry. Briefly, 48 h post-transfection, SiHa cells transfected with oe TMEM132A, sh TMEM132A, or respective controls (vector and sh NC) were collected, rinsed twice with cold PBS, and an overnight fixation was conducted in 70% ice-cold ethanol at 4 °C. Then, fixed cells were centrifuged, resuspended in PBS with 100 µg/mL RNase A (Sigma-Aldrich) and 50 µg/mL PI (BD Biosciences), and incubation was conducted (30 min, 37 °C, darkness). Cell cycle profiles were estimated via a BD FACSCanto II flow cytometer (BD Biosciences), and data processing was conducted with FlowJo for quantifying the cell percentages in G0/G1, S, and G2/M phases. Wound healing assay Cell migration was estimated via a scratch wound healing assay. SiHa cells transfected with oeTMEM132A, shTMEM132A, or controls (vector and shNC) were grown in 6-well plates (5 × 10⁵ cells/well) and cultivated to 90%–100% confluency. A sterile 200 µL pipette tip was utilized to form a straight scratch, and the removal of detached cells was conducted with three PBS washes. New serum-free medium was applied, and wound closure was imaged at 0 and 24 h via an inverted phase-contrast microscope (Nikon Eclipse Ti2) at 10× magnification. Wound areas were quantified in ImageJ (NIH) by measuring the remaining scratch width at three predefined positions per well. Cell invasion assay Cell invasion capacity was estimated via Transwell chambers (8 μm pore size; Corning) pre-coated with Matrigel (BD Biosciences). Briefly, SiHa cells transfected with oe TMEM132A, sh TMEM132A, or respective controls (vector and sh NC) were serum-starved for 12 h. Cells (5 × 104 cells/well) in 200 µL serum-free medium were inserted into the top chamber. The bottom chamber was occupied with 600 µL complete medium with 20% FBS as a chemoattractant. A 48-h post-incubation at 37 °C, a cotton swab was utilized to remove the non-invaded cells on the membrane’s top surface. Invaded cells on the bottom surface underwent fixing with 4% paraformaldehyde for 15 min, staining with 0.1% crystal violet for 20 min, and rinsing twice with PBS. An inverted microscope (Nikon Eclipse Ti2) was utilized to photograph stained cells at 10× magnification. Invaded cells from 5 random fields/well were counted via ImageJ (NIH). Invasion ability was represented as the average count of invaded cells/field. Statistical analysis For data analysis, GraphPad Prism 9.0 was employed. Experimental outcomes derived from 3 independent replicates are reported as mean ± standard deviation (SD). A two-tailed unpaired Student’s t-test was employed for two-group comparison. When assessing variations across several groups, one-way ANOVA and then Tukey’s post hoc test were utilized. P < 0.05 was deemed as significance. Data distribution normality and variance homogeneity were confirmed prior to parametric testing. Results TMEM132A is highly expressed in CC Profiling of TMEM132A expression across numerous malignancies via the TCGA database illustrated significantly higher levels in tumor tissues than in neighboring healthy tissues, with CC displaying one of the most marked differences (Fig. 1A). Integrated analysis of both TCGA and GEO datasets further confirmed a significant overexpression of TMEM132A in CC tissues compared to controls (Fig. 1B, C). ROC curve analysis illustrated strong diagnostic capabilities, with an area under the curve (AUC) of 0.969 (Fig. 1D). These findings were supported by validation in clinical samples, which showed heightened mRNA and protein levels of TMEM132A in tumor tissues compared to matched neighboring healthy tissues (Fig. 1E, F and Supplementary Fig. 1 A, B). In vitro analyses indicated that CC cell lines (C-33 A, CaSki, and SiHa) expressed markedly higher levels of TMEM132A than normal cervical epithelial cells. Among these, SiHa cells displayed the highest expression and were chosen for following investigations (Fig. 1G, H). Fig. 1TMEM132A is Highly Expressed in Cervical Cancer. (A) Box plots showing TMEM132A expression (log2(FPKM + 1)) in normal and tumor tissues across multiple cancer types. (B–C) TMEM132A mRNA levels in tumor vs. normal tissues depending on TCGA and GEO datasets. (D) ROC curve analysis assessing the diagnostic capability of TMEM132A in distinguishing cervical cancer from normal tissues. (E–F) TMEM132A protein and mRNA expression in tumor and neighboring healthy tissues measured by western blot and qRT-PCR (n = 3). (G–H) TMEM132A protein and mRNA levels in 4 cervical cancer cell lines (HceEpic, C-33 A, CaSki, SiHa). Data are reported as mean ± SD; unpaired t-tests were employed for two-group comparisons. p < *0.05; ** 0.01; *** 0.001. TMEM132A is Highly Expressed in Cervical Cancer. (A) Box plots showing TMEM132A expression (log2(FPKM + 1)) in normal and tumor tissues across multiple cancer types. (B–C) TMEM132A mRNA levels in tumor vs. normal tissues depending on TCGA and GEO datasets. (D) ROC curve analysis assessing the diagnostic capability of TMEM132A in distinguishing cervical cancer from normal tissues. (E–F) TMEM132A protein and mRNA expression in tumor and neighboring healthy tissues measured by western blot and qRT-PCR (n = 3). (G–H) TMEM132A protein and mRNA levels in 4 cervical cancer cell lines (HceEpic, C-33 A, CaSki, SiHa). Data are reported as mean ± SD; unpaired t-tests were employed for two-group comparisons. p < *0.05; ** 0.01; *** 0.001. TMEM132A promotes CC cell proliferation and cell cycle progression We utilized two distinct lentiviral shRNA sequences targeting TMEM132A to assess its functional role in CC cells. Transfection efficiency for TMEM132A overexpression and knockdown was verified by Western blot and qRT-PCR (Figs. 2A-B). TMEM132A overexpression significantly enhanced the growth of SiHa cells, as detected by CCK-8 assays (Fig. 2C), while knockdown of TMEM132A suppressed cell growth. Cell cycle analysis showed that TMEM132A overexpression elevated the S-phase population and reduced the cell percentages in the G0/G1 phase, whereas TMEM132A knockdown induced G0/G1 arrest (Fig. 2D). These findings indicate that TMEM132A promotes CC progression by facilitating cell cycle transition and enhancing proliferation. The results obtained with the second shRNA sequence were consistent with those from the first, further supporting the functional impact of TMEM132A knockdown (Supplementary Fig. 2 A, B, C). Fig. 2TMEM132A Enhances Cervical Cancer Cell Proliferation and Cell Cycle Progression. (A–B) TMEM132A protein and mRNA expression after overexpression or knockdown, assessed by western blot and qRT-PCR. (C) CCK-8 assessments evaluating the influences of TMEM132A modulation on cell growth. (D) Flow cytometry analysis of cell cycle distribution after TMEM132A overexpression or suppression. Data are reported as mean ± SD; unpaired t-tests were employed for two-group comparisons. *p < 0.05. TMEM132A Enhances Cervical Cancer Cell Proliferation and Cell Cycle Progression. (A–B) TMEM132A protein and mRNA expression after overexpression or knockdown, assessed by western blot and qRT-PCR. (C) CCK-8 assessments evaluating the influences of TMEM132A modulation on cell growth. (D) Flow cytometry analysis of cell cycle distribution after TMEM132A overexpression or suppression. Data are reported as mean ± SD; unpaired t-tests were employed for two-group comparisons. *p < 0.05. TMEM132A enhances CC cell migration and invasion Functionally, TMEM132A overexpression significantly accelerated SiHa cell migration, whereas TMEM132A knockdown reduced migratory capacity (Fig. 3A). Similarly, Transwell invasion assays illustrated that TMEM132A upregulation elevated the count of invasive cells, while TMEM132A knockdown inhibited invasion (Fig. 3B). These results underscore the essential function of TMEM132A in promoting the metastatic potential of CC cells. The second shRNA sequence also yielded comparable results, confirming the consistency of the observed phenotypes (Supplementary Fig. 2D, E). Fig. 3TMEM132A Triggers the Capabilities of Cervical Cancer Cells to Migrate and Invade. (A) Wound-healing assays showing changes in migratory capacity after TMEM132A overexpression or knockdown (0 h, 24 h). (B) Transwell assays evaluating TMEM132A-dependent effects on cell invasion. Data are represented as mean ± SD; unpaired t-tests were employed for two-group comparisons. *p < 0.05. TMEM132A Triggers the Capabilities of Cervical Cancer Cells to Migrate and Invade. (A) Wound-healing assays showing changes in migratory capacity after TMEM132A overexpression or knockdown (0 h, 24 h). (B) Transwell assays evaluating TMEM132A-dependent effects on cell invasion. Data are represented as mean ± SD; unpaired t-tests were employed for two-group comparisons. *p < 0.05. Functional enrichment analysis of TMEM132A in CC Functional enrichment analysis of genes co-expressed with TMEM132A revealed several distinct molecular pathways potentially involved in CC progression. Volcano plot analysis determined a set of genes that had a significant upregulation or downregulation in TMEM132A-high tumors, with several key candidates highlighted (Fig. 4A). A heatmap further illustrated the differential expression patterns of these genes in tumor and healthy tissues, demonstrating strong correlations with TMEM132A expression levels (Fig. 4B). KEGG analysis of the upregulated genes showed enrichment in cancer-correlated pathways (e.g., the PI3K-AKT pathway, proteoglycans in cancer, and focal adhesion) suggesting that TMEM132A may participate in tumor growth and metastasis (Fig. 4C). GO analysis identified enriched biological processes (cell-matrix adhesion, extracellular matrix organization, and epithelial tube formation) which are consistent with a pro-invasive phenotype (Fig. 4D). In contrast, analysis of downregulated genes revealed KEGG pathway enrichment in immune-related processes (Fig. 4E), and GO terms included lymphocyte chemotaxis, apoptosis, and activation of immune responses, indicating that TMEM132A may exert immunosuppressive effects in CC (Fig. 4F). Fig. 4Functional Enrichment Analysis of TMEM132A in Cervical Cancer. (A) Volcano plot of DEGs following TMEM132A overexpression or knockdown. (B) Heatmap showing expression patterns of DEGs. C–F, KEGG and GO of upregulated (C, D) and suppressed (E, F) genes. Functional Enrichment Analysis of TMEM132A in Cervical Cancer. (A) Volcano plot of DEGs following TMEM132A overexpression or knockdown. (B) Heatmap showing expression patterns of DEGs. C–F, KEGG and GO of upregulated (C, D) and suppressed (E, F) genes. TMEM132A activates the FAK/PI3K/AKT pathway To examine the molecular mechanisms through which TMEM132A affects CC progression, the stimulation status of the FAK/PI3K/AKT pathway was examined. Gene Set Enrichment Analysis (GSEA) illustrated significant enrichment of genes linked to focal adhesion (Fig. 5A) and the PI3K/AKT pathway (Fig. 5B). To confirm these outcomes, Western blotting was conducted to estimate the phosphorylation levels of main pathway components. TMEM132A overexpression significantly elevated the phosphorylation levels of FAK, PI3K, and AKT (Fig. 5C), whereas TMEM132A knockdown resulted in reduced phosphorylation of these proteins (Fig. 5D). Notably, pharmacological blockade with the FAK inhibitor Y15 effectively abolished TMEM132A-induced phosphorylation of FAK, PI3K, and AKT, and concurrently reversed the enhanced invasive capacity, confirming the dominant role of this signaling cascade (Supplementary Fig. 3 A, B). These results strongly support the conclusion that TMEM132A promotes CC progression, at least partially, via stimulation of the FAK/PI3K/AKT pathway. Fig. 5TMEM132A Activates the FAK/PI3K/AKT Pathway. (A-B) GSEA showing enrichment of focal adhesion and PI3K/AKT pathway genes following TMEM132A overexpression. (C-D) Western blot analysis of key focal adhesion and PI3K/AKT signaling proteins after TMEM132A overexpression or suppression. Data are reported as mean ± SD. Unpaired t-tests were employed for comparisons. *p < 0.05. TMEM132A Activates the FAK/PI3K/AKT Pathway. (A-B) GSEA showing enrichment of focal adhesion and PI3K/AKT pathway genes following TMEM132A overexpression. (C-D) Western blot analysis of key focal adhesion and PI3K/AKT signaling proteins after TMEM132A overexpression or suppression. Data are reported as mean ± SD. Unpaired t-tests were employed for comparisons. *p < 0.05. TMEM132A regulates HOMER3 expression in CC To identify key downstream effectors of TMEM132A, we integrated TCGA/GEO co-expression networks with functional enrichment data. Among the top correlated candidates, HOMER3 was prioritized due to its strong positive correlation with TMEM132A, its known function as a scaffold protein organizing focal adhesion and kinase signaling complexes, and its significant upregulation in our clinical validation, making it the most compelling target for mechanistic dissection. Co-expression analysis of TCGA data identified HOMER3 as a top gene strongly correlated with TMEM132A in CC (Fig. 6A). Scatter plot analysis confirmed a significant positive association between TMEM132A and HOMER3 expression levels across tumor tissues (Fig. 6B). Moreover, TCGA data illustrated that HOMER3 was significantly overexpressed in CC tissues compared to controls (Fig. 6C). Western blot analysis further demonstrated elevated HOMER3 protein levels in tumor tissues compared to neighboring healthy tissues in three representative patient samples (Fig. 6D and Supplementary Fig. 1 C), which was corroborated by qRT-PCR showing increased HOMER3 mRNA expression in tumor specimens (Fig. 6E and Supplementary Fig. 1D). To validate the knockdown efficiency, qRT-PCR confirmed a substantial reduction in HOMER3 mRNA levels following shRNA-mediated silencing (Fig. 6F). Importantly, Western blot assays illustrated that TMEM132A upregulation significantly increased HOMER3 protein levels, while TMEM132A suppression resulted in a marked decrease (Fig. 6G), indicating that TMEM132A positively regulates HOMER3 expression at the transcriptional and translational levels. To further validate the molecular association between TMEM132A and HOMER3, Co-IP assays were performed. The results demonstrated that TMEM132A specifically co-precipitated with HOMER3, confirming a direct physical interaction or stable complex formation between these two proteins in CC cells (Supplementary Fig. 4D). To comprehensively examine the function of HOMER3, we assessed its impact on CC cell migration, proliferation, and invasion. Our results illustrated that HOMER3 suppression significantly inhibited the migratory and invasive capacities of CC cells, as well as their proliferative potential, supporting its multifaceted oncogenic role in tumor progression (Supplementary Fig. 4 A, B and C). These outcomes illustrate that HOMER3 contributes to the metastatic potential of CC and functions downstream of TMEM132A in this process. Fig. 6TMEM132A Regulates HOMER3 Expression in Cervical Cancer. (A) Heatmap of the top 10 genes positively correlated with TMEM132A. (B) Correlation between TMEM132A and HOMER3 expression. (C) HOMER3 expression in normal versus tumor tissues (TCGA). (D–E) Western blot and qRT-PCR of HOMER3 expression in 3 paired tumor and neighboring healthy tissues. (F) qRT-PCR analysis of HOMER3 expression after HOMER3 knockdown. (G) Western blot analysis of HOMER3 expression after TMEM132A upregulation or downregulation. Data are reported as mean ± SD. Unpaired t-tests were employed for comparisons. *p < 0.05. TMEM132A Regulates HOMER3 Expression in Cervical Cancer. (A) Heatmap of the top 10 genes positively correlated with TMEM132A. (B) Correlation between TMEM132A and HOMER3 expression. (C) HOMER3 expression in normal versus tumor tissues (TCGA). (D–E) Western blot and qRT-PCR of HOMER3 expression in 3 paired tumor and neighboring healthy tissues. (F) qRT-PCR analysis of HOMER3 expression after HOMER3 knockdown. (G) Western blot analysis of HOMER3 expression after TMEM132A upregulation or downregulation. Data are reported as mean ± SD. Unpaired t-tests were employed for comparisons. *p < 0.05. HOMER3 mediates TMEM132A-driven cancer progression Rescue experiments demonstrated that HOMER3 knockdown effectively reversed the TMEM132A-mediated stimulation of the FAK/PI3K/AKT pathway. While TMEM132A overexpression significantly increased the phosphorylation levels of FAK, PI3K, and AKT, co-transfection with HOMER3-targeting shRNA abrogated these effects (Fig. 7A). Conversely, ectopic overexpression of HOMER3 in TMEM132A-depleted cells effectively restored FAK/PI3K/AKT phosphorylation (Supplementary Fig. 1E). Functional recovery assays further revealed that HOMER3 knockdown attenuated the oncogenic phenotypes induced by TMEM132A. Specifically, TMEM132A overexpression promoted cell proliferation and invasion, whereas these effects were markedly diminished upon HOMER3 silencing (Fig. 7B, C). Taken together, these results identify HOMER3 as a key downstream mediator of TMEM132A and demonstrate its essential role in transmitting TMEM132A-driven tumorigenic signals through the FAK/PI3K/AKT pathway. Fig. 7HOMER3 Mediates TMEM132A-Driven Cervical Cancer Progression. (A) Western blot analysis of p-FAK/FAK, p-PI3K/PI3K, and p-AKT/AKT following TMEM132A or HOMER3 overexpression or knockdown. (B) Transwell invasion assays showing changes in invasive capacity under the same conditions. (C) CCK-8 proliferation assays evaluating TMEM132A- and HOMER3-dependent effects on cell growth. Data are reported as mean ± SD. Unpaired t-tests were employed for comparisons. *p < 0.05. HOMER3 Mediates TMEM132A-Driven Cervical Cancer Progression. (A) Western blot analysis of p-FAK/FAK, p-PI3K/PI3K, and p-AKT/AKT following TMEM132A or HOMER3 overexpression or knockdown. (B) Transwell invasion assays showing changes in invasive capacity under the same conditions. (C) CCK-8 proliferation assays evaluating TMEM132A- and HOMER3-dependent effects on cell growth. Data are reported as mean ± SD. Unpaired t-tests were employed for comparisons. *p < 0.05. Discussion CC remains a major global health burden, with persistent high-risk HPV infection recognized as the primary etiological factor17. HPV infection induces genomic instability and malignant transformation in cervical epithelial cells, ultimately leading to the development of CC18. Vaccination is a crucial strategy in CC prevention. Currently, the HPV vaccine has been highly efficient in preventing HPV infection and its associated precursors to CC. By vaccinating against HPV, particularly types 16 and 18, the risk of infection can be significantly reduced, thereby lowering the occurrence of CC19. Moreover, regular screening and early treatment of cervical precancers, especially within high-risk populations, have been proven to reduce the incidence of CC20. Therefore, the prevention and early diagnosis of CC are key to reducing its burden. Future research is likely to focus on the molecular mechanisms underlying CC development, with the goal of further lowering the occurrence and deaths of CC worldwide. The TMEM132 protein family, comprising evolutionarily conserved transmembrane proteins, regulates cell adhesion and signaling through unique domain architectures21. Among these, TMEM132A stands out due to its distinctive molecular features: its extracellular region contains three bacterial immunoglobulin-like (BIG) domains and a cohesin domain, while the intracellular region harbors a PP1 phosphatase docking site and a WIRS actin regulatory motif22,23. These structural characteristics suggest its potential role in integrating extracellular matrix signals with cytoskeletal remodeling to modulate the tumor microenvironment. Latest investigations have underlined the oncogenic potential of TMEM132A across multiple cancers. In gastric cancer, TMEM132A drives the growth and metastasis of tumors by stimulating the Wnt/β-catenin pathway24. in prostate cancer, its expression correlates with cancer-associated fibroblast (CAF) infiltration and acts as a predictive biomarker25. In bladder cancer, its upregulation is related to tumor progression and immune microenvironment reprogramming26. Collectively, these findings underscore TMEM132A’s multifaceted role in malignant progression. This investigation systematically elucidates the pivotal function of TMEM132A in CC for the first time. Integrated multi-omics analyses (TCGA/GEO) and experimental confirmation validated its specific upregulation in CC tissues and cell lines, with remarkable diagnostic efficacy. Functional assays further demonstrated that TMEM132A overexpression accelerates S-phase progression and significantly enhances the aggressiveness of cervical malignant cells. Mechanistically, we illustrated that TMEM132A drives malignant phenotypes by stimulating the FAK/PI3K/AKT pathway—overexpression of TMEM132A markedly increased phosphorylation levels of p-FAK, p-PI3K, and p-AKT, whereas knockdown produced the opposite effect. This discovery expands the functional understanding of TMEM132A as an upstream regulator. Intriguingly, while TMEM132A exhibits heterogeneity in downstream targets across cancer types, its conserved regulation of cell cycle dynamics and motility suggests its potential role as a pan-oncogene. Upcoming investigations should confirm its diagnostic robustness in bigger clinical groups and examine whether TMEM132A governs CC progression via additional mechanisms, such as non-coding RNA interactions or epigenetic modifications. The HOMER family comprises evolutionarily conserved adaptor proteins, including HOMER1, HOMER2, and HOMER3. These proteins interact with target proteins containing specific motifs through their N-terminal EVH1 domain and mediate oligomerization via their C-terminal coiled-coil domain. They play essential roles in postsynaptic signal transduction and cell adhesion27. The long HOMER protein isoforms, such as HOMER1b/c and HOMER3a/b, regulate calcium signaling and synaptic plasticity by stabilizing multiprotein complexes, whereas the short isoforms, such as HOMER1a, are expressed activity-dependently and competitively disrupt the function of long isoforms, thereby modulating synaptic dynamics28,29. Among them, HOMER3 is a key family member that is highly enriched in cerebellar Purkinje cells. It forms complexes with metabotropic glutamate receptors (mGluR1α/5), IP3 receptors, and actin-binding proteins, thereby regulating calcium homeostasis and synaptic remodeling. Its C-terminal coiled-coil domain facilitates polymerization and contributes to the spatial organization of signaling pathways30. Recent studies have reported overexpression of HOMER3 in breast cancer, bladder cancer, and hepatocellular carcinoma31–33. Nevertheless, its function and oncogenic mechanisms in CC remain incompletely understood. Herein, we found that HOMER3 is significantly elevated in CC and functionally related to TMEM132A. In line with this observation, HOMER3 expression was noticeably higher in CC tissues and cell lines than in normal controls, and its levels were positively related to those of TMEM132A. Further mechanistic investigations revealed that TMEM132A promotes the stimulation of the FAK/PI3K/AKT pathway by controlling HOMER3 expression, thereby enhancing the aggressiveness of CC cells. Notably, HOMER3 knockdown effectively reversed the oncogenic effects induced by TMEM132A overexpression, confirming that HOMER3 acts as a main downstream effector of TMEM132A. To our knowledge, this investigation presents the 1 st evidence of HOMER3’s oncogenic role in CC and expands its known functions beyond the neuronal context. The identified TMEM132A–HOMER3 regulatory axis may offer novel insights into the molecular subtyping and targeted therapy of CC. Despite these promising findings, several limitations warrant acknowledgment. First, although we have expanded our clinical validation cohort to six paired samples to strengthen the preliminary evidence, the sample size remains relatively modest, and comprehensive stratified analyses correlating TMEM132A and HOMER3 expression with clinical stages, histological subtypes, and HPV statuses will require a larger, multi-center cohort. Second, the current mechanistic insights are primarily derived from in vitro cellular models. While conventional subcutaneous xenografts are widely used, they may not fully recapitulate the unique anatomical microenvironment of cervical cancer; therefore, our team is currently establishing a murine orthotopic cervical cancer model for rigorous in vivo validation in follow-up studies. Third, although Co-IP assays confirm a physical interaction between TMEM132A and HOMER3, the precise upstream regulatory layer—whether mediated by transcriptional activation, post-translational stabilization, or non-coding RNA networks—remains to be fully dissected. Our preliminary data suggest a multi-tiered regulatory mechanism that requires extensive multi-omics integration and systematic validation, which is currently underway and will be the focus of a dedicated subsequent investigation. Additionally, while SiHa cells provided a consistent and clinically relevant model for both gain- and loss-of-function studies, future validation of TMEM132A overexpression in low-endogenous lines will further confirm the broad applicability of our findings across diverse CC molecular subtypes. We acknowledge these limitations and are committed to addressing them in our ongoing research to fully translate the TMEM132A–HOMER3 axis into clinical applications. Conclusion This investigation considers TMEM132A as a main driver of CC progression via HOMER3-mediated stimulation of the FAK/PI3K/AKT pathway. Our outcomes illustrated that TMEM132A is markedly elevated in CC tissues and cell lines, and its expression is strictly linked to aggressive tumor phenotypes. Functional analyses revealed that TMEM132A increases cell aggressiveness and S-phase progression, whereas its knockdown significantly attenuates these oncogenic effects. Mechanistically, TMEM132A positively regulates the HOMER3 expression, which in turn stimulates the FAK/PI3K/AKT signaling cascade. Rescue experiments further confirmed that silencing HOMER3 effectively abrogates TMEM132A-induced pathway activation and malignant cellular behaviors. These findings identify TMEM132A as a candidate molecular marker for future clinical evaluation and a potential target for subsequent therapeutic exploration in CC, with HOMER3 functioning as a key downstream effector. This study not only expands the current understanding of TMEM132A’s oncogenic functions but also highlights the TMEM132A–HOMER3–FAK/PI3K/AKT signaling axis as a mechanistic framework worthy of further preclinical and clinical investigation. Upcoming investigations should concentrate on the clinical validation of TMEM132A and HOMER3 as biomarkers and further explore their interactions with other pathways and components of the tumor microenvironment to refine targeted treatment strategies for CC. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3